Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

US appeals court upholds AstraZeneca’s Seroquel XR patent

Says patent on unique formulation of antidepressant is valid

- PMLiVE

Merck settles Vytorin lawsuit for $688m

Had faced claims it held back negative data from clinical trials

- PMLiVE

Merck & Co extends autoimmune collaboration with Lycera

New deal could be worth more than $300m to the US biopharma company

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

Novartis building

Novartis’ Jakavi turned down by NICE for blood cancer

UK cost-effectiveness watchdog concerned about 'uncertainties' in data in draft guidance

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

- PMLiVE

SMC approves Eliquis, restricts use of Rienso

Pfizer-BMS' anticoagulant backed but Takeda's drug given second-line recommendation

- PMLiVE

Shire pays $48m to settle generic Adderall XR claims with Impax

Avoids court battle over supply issues

- PMLiVE

Interview: Cesar Rodriguez, Janssen

Managing director of Janssen UK & Ireland, Cesar Rodriguez is relishing being in the UK market, after years working across Europe and North Africa

- PMLiVE

Merck blocks Mylan’s generic Zetia and Vytorin after appeal

Keeps patents of cholesterol medicines protected until April 2017

Sanofi’s Steve Oldfield to co-chair UK medicines access group

Takes over from UCB’s Matthew Speers in joint government/industry group

- PMLiVE

Merck KGaA and Opexa enter MS deal

Will develop personalised T-cell based medicine Tcelna

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links